绝经后女性白介素-6、性激素水平与冠状动脉钙化程度的关系

Level of interleukin-6 and sex hormone is related to severity of coronary artery calcium in postmenopausal female

目的 探讨女性绝经后性激素、IL-6水平变化与冠状动脉（冠脉）钙化程度的关系.方法连续入选142例绝经2年以上初诊为冠心病的女性患者.患者行冠脉CT检查,分为观察组（存在冠脉钙化,97例）和对照组（无冠脉钙化,45例）.根据冠脉钙化积分（CACS）将观察组分为三个亚组低冠状动脉钙化组（CACS 1～100）26例、中冠脉钙化组（CACS 101～400）49例、高冠脉钙化组（CACS〉400）22例.检测及分析不同组别患者血清雌二醇（E2）、睾酮（T）、白细胞介素（IL-6）水平.结果 与对照组比较,观察组患者血清E2水平明显降低、IL-6水平显著升高,差异均有统计学意义（P均〈0.05）;两组患者睾酮水平无统计学差异（P〉0.05）.随冠脉钙化程度加重,血清E2水平逐渐降低、血清IL-6水平逐渐增高（P均〈0.05）;不同冠脉钙化积分组血清睾酮水平变化幅度较小,组间无统计学差异（P〉0.05）.结论 绝经后女性冠心病患者冠脉程度与IL-6、E2水平关系密切,E2可能通过抑制冠脉斑块炎症活动影响冠心病的发展.

Objective To investigate relationship between sex hormones, interleukin 6 （IL-6） level and severityof coronary artery calcium in postmenopausal female. Methods 142 newly diagnosed female patients with coronaryheart disease （CHD） who were postmenopausal over 2 years were enrolled. All patients received coronary arterycomputerized tomography （CT）, and were divided into two groups the experiment group （97 cases with coronary arterycalcification）, and the control group （45 cases without coronary artery calcification）. And based on the coronary arterycalcium score（CACS）, the experiment group was further divided into 3 groups： the low CACS group （CACS 1-100,26cases）, the medium CACS group （CACS 101-400,49 cases）, the high CACS group （22 cases）. Blood estradiol （E2）,testosterone （T） and interleukin 6 （IL-6） were measured and then analyzed in all groups. Results Compared with thecontrol group, E2 of experiment group was significantly decreased, and IL-6 was significantly increased （P〈0.05）. Nodifference of T was shown in experiment group and control group （P〉0.05）. With the aggravating degree of coronaryartery calcium score, the serum E2 level is gradually reduced; the level of IL-6 is gradually increased （P〈0.05）. Nodifference of T was shown among three CACS groups （P〉0.05）. Conclusion The degree of coronary artery calcium inpostmenopausal women is highly related with IL-6 and E2. E2 may help to curb the development of CHD by inhibitingthe expression of the inflammation activity of the coronary.